In vitro activity of garenoxacin against recent clinical isolates of Chlamydia pneumoniae.
The in vitro activities of garenoxacin, a novel des-F (6)-quinolone, levofloxacin, moxifloxacin and clarithromycin were tested against 30 recent clinical isolates of Chlamydia pneumoniae. The minimal inhibitory concentration (MIC) at which 90% of the isolates were inhibited and the minimal bactericidal concentration (MBC) at which 90% of the isolates were killed by garenoxacin for C. pneumoniae was 0.03 mg/l (range 0.015-0.03 mg/l).
Roblin
Patricia M
PM
Division of Infectious Diseases, Department of Pediatrics, State University of New York Downstate Medical Center, Box 49, 450 Clarkson Avenue, Brooklyn, NY 11203-2098, USA.
Reznik
Tamara
T
Hammerschlag
Margaret R
MR
D000328:Adult; D000890:Anti-Infective Agents / Q000494:pharmacology*; D002170:Canada; D023521:Chlamydophila Infections / Q000382:microbiology*; D016993:Chlamydophila pneumoniae / Q000187:drug effects* / Q000302:isolation & purification; D017714:Community-Acquired Infections / Q000382:microbiology; D024841:Fluoroquinolones; D006801:Humans; D007211:Indoles / Q000494:pharmacology*; D007564:Japan; D008826:Microbial Sensitivity Tests; D018410:Pneumonia, Bacterial / Q000382:microbiology; D015363:Quinolones / Q000494:pharmacology*; D014481:United States
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D007211:Indoles; D015363:Quinolones; C419689:garenoxacin